[1]李梦毓,耿 巍,闫少华,等.依洛尤单抗对ACS患者有效性及安全性的Meta分析[J].医学信息,2024,37(02):35-40,46.[doi:10.3969/j.issn.1006-1959.2024.02.006]
　LI Meng-yu,GENG Wei,YAN Shao-hua,et al.Meta-analysis of the Efficacy and Safety of Evolocumab in Patients with ACS[J].Journal of Medical Information,2024,37(02):35-40,46.[doi:10.3969/j.issn.1006-1959.2024.02.006]
点击复制

依洛尤单抗对ACS患者有效性及安全性的Meta分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年02期
页码:
35-40,46
栏目:
医学数据科学
出版日期:
2024-01-15

文章信息/Info

Title:
Meta-analysis of the Efficacy and Safety of Evolocumab in Patients with ACS
文章编号:
1006-1959（2024）02-0035-07
作者:
李梦毓; 耿 巍; 闫少华; 等
（1.承德医学院研究生学院，河北 承德 067000；2.保定市第一中心医院心内科，河北 保定 071000）
Author(s):
LI Meng-yu; GENG Wei; YAN Shao-hua; et al.
(1.Graduate School of Chengde Medical University,Chengde 067000,Hebei,China;2.Department of Cardiology,Baoding First Central Hospital,Baoding 071000,Hebei,China)
关键词:
依洛尤单抗; AMG 145; 瑞百安; 急性冠脉综合征
Keywords:
Evolocumab; AMG 145; Repatha; Acute coronary syndrome
分类号:
R541.4
DOI:
10.3969/j.issn.1006-1959.2024.02.006
文献标志码:
A
摘要:
目的 系统评价依洛尤单抗治疗急性冠脉综合征（ACS）患者的有效性与安全性。方法 检索CNKI、万方、维普、PubMed、EMBASE、Cochrane Library等中英文数据库中依洛尤单抗用于治疗ACS患者的随机对照试验，检索时限为建库至2023年4月15日，按照纳入与排除标准筛选所检索文献并提取相关数据，根据Cocharane偏倚风险评估表评价纳入文献的偏倚风险；使用Review Manager5.4软件对最终纳入的文献数据进行定量分析。结果 共纳入10项随机对照试验，共1318例患者。Meta分析结果显示，与对照组相比，依洛尤单抗显著降低了ACS患者因再发心绞痛的住院时间[OR=0.26，95%CI（0.12，0.58），P=0.001]，降低了患者的LDL-C水平[MD=-1.06，95%CI（-1.51，-0.61），P=0.000]及hs-CRP水平[MD=-0.44，95%CI（-0.70，-0.18），P＝0.0008]；但在降低急性心肌梗死发生率[OR=0.68，95%CI（0.31，1.49），P=0.34]、冠状动脉重建率[OR=0.69，95%CI（0.42，1.14），P=0.15]、心血管死亡率[OR=0.90，95%CI（0.34，2.38），P=0.83]、卒中发生率[OR=0.99，95%CI（0.32，3.10），P=0.99]以及不良反应发生率[OR=1.16，95%CI（0.68，1.95），P=0.59]方面没有表现出明显优势。结论 依洛尤单抗可以有效降低ACS患者的血脂指标、炎症指标、因再发心绞痛住院率，然而在降低急性心肌梗死发生率、冠状动脉重建率、心血管死亡率、卒中发生率及发生药物不良反应等方面并未表现出明显优势。
Abstract:
Objective To systematically review the efficacy and safety of evolocumab in patients with acute coronary syndrome(ACS).Methods CNKI, Wanfang, VIP, PubMed, EMBASE, Cochrane Library and other Chinese and English databases were searched for randomized controlled trials of evolocumab in the treatment of ACS patients. The retrieval time was from the establishment of the database to April 15,2023.According to the inclusion and exclusion criteria, the retrieved literature was screened and relevant data were extracted. The risk of bias of the included literature was evaluated according to the Cocharane bias risk assessment form. Review Manager 5.4 software was used to quantitatively analyze the final selected literature data.Results A total of 10 randomized controlled trials involving 1318 patients were included. The results of Meta-analysis showed that compared with the control group, eloizumab significantly reduced the length of hospital stay due to recurrent angina pectoris in ACS patients [OR=0.26,95%CI(0.12,0.58),P=0.001], reduced LDL-C levels [MD=-1.06,95%CI(-1.51,-0.61),P=0.000] and hs-CRP levels [MD=-0.44,95%CI(-0.70,-0.18),P=0.0008]; However, there was no significant advantage in reducing the incidence of acute myocardial infarction [OR=0.68,95%CI(0.31,1.49),P=0.34], coronary artery reconstruction rate [OR=0.69,95%CI(0.42,1.14),P=0.15], cardiovascular mortality [OR=0.90,95%CI(0.34,2.38),P=0.83], stroke incidence [OR=0.99,95%CI(0.32,3.10),P=0.99] and adverse reactions [OR=1.16,95%CI(0.68,1.95),P=0.59].Conclusion Evolocumab can effectively reduce the blood lipid index, inflammation index and hospitalization rate of recurrent angina pectoris in ACS patients. However, there was no significant difference in reducing the incidence of acute myocardial infarction, coronary artery reconstruction rate, cardiovascular mortality, stroke incidence and adverse drug reactions.

参考文献/References:

[1]中华医学会心血管病学分会动脉粥样硬化与冠心病学组,中华心血管病杂志编辑委员会.超高危动脉粥样硬化性心血管疾病患者血脂管理中国专家共识[J].中华心血管病杂志,2020,48(4):280-286.[2]American Diabetes Association.10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2019[J].Diabetes Care,2019,42(Suppl 1):S103-S123.[3]Shiraishi J,Matsubara Y,Hyogo M,et al.Stent-less percutaneous coronary intervention using rotational atherectomy to the noncalcified occlusive lesion with recanalized thrombus[J].Coron Artery Dis,2020,31(7):661-664.[4]Londregan AT,Wei L,Xiao J,et al.Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents[J].J Med Chem,2018,61(13):5704-5718.[5]Bergeron N,Phan BA,Ding Y,et al.Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk[J].Circulation,2015,132(17):1648-1666.[6]Fala L.Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia[J].Am Health Drug Benefits,2016,9(Spec Feature):136-139.[7]Chan JC,Piper DE,Cao Q,et al.A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates[J].Proc Natl Acad Sci U S A,2009,106(24):9820-9825.[8]谈礼武,阳维德,王新云,等.急性冠脉综合征患者外周血前蛋白转化酶枯草溶菌素9水平及其对患者预后的预测价值[J].广西医学,2020,42(15):1954-1958..[9]Sabatine MS,Giugliano RP,Keech AC,et al.Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease[J].N Engl J Med,2017,376(18):1713-1722.[10]张新超,于学忠,陈凤英,等.急性冠脉综合征急诊快速诊治指南(2019)[J].中国急救医学,2019,39(4):301-308.[11]Koskinas KC,Windecker S,Pedrazzini G,et al.Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)[J].J Am Coll Cardiol,2019,74(20):2452-2462.[12]Hao Y,Yang YL,Wang YC,et al.Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome[J].Int Heart J,2022,63(4):669-677.[13]杨华,陈妍妍,魏高利,等.前蛋白转化酶枯草溶菌素9抑制剂在急性心肌梗死行经皮冠状动脉介入治疗患者中的应用效果[J].心脏杂志,2020,32(5):480-484.[14]林智海,王正东,李平,等.前蛋白转化酶枯草溶菌素9抑制剂-依洛尤单抗对急性冠状动脉综合征患者血脂谱及血管内皮功能的影响[J].河北医学,2021,27(3):508-512.[15]赵岩,惠慧,孙仕泽,等.依洛尤单抗联合他汀类药物治疗对急性冠状动脉综合征患者降脂效果及预后的影响[J].中国医药,2021,16(11):1622-1625.[16]付宝军.依洛尤单抗在急性冠状动脉综合征经皮冠状动脉介入治疗术后患者中的应用价值[D].济宁:济宁医学院,2021.[17]叶壮.依洛尤单抗在高龄急性冠脉综合征行PCI患者中的应用研究[D].郑州:河南大学,2021.[18]申晨,王晓丽,张晓玉,等.依洛尤单抗联合瑞舒伐他汀对急性心肌梗死患者PCI后血脂、血管内皮功能的影响[J].疑难病杂志,2022,21(9):907-911,926.[19]陈文山,姬劲锐,魏小云,等.早期应用PCSK9抑制剂对非ST段抬高型急性冠状动脉综合征患者PCI后炎症水平和微循环功能的影响[J].中国动脉硬化杂志,2022,30(7):601-605.[20]王均强,董少华,阿丽娜,等.依洛尤单抗联合他汀类药物治疗急性冠脉综合征患者高血脂的疗效与安全性评价[J].解放军医学院学报,2022,43(1):6-10.[21]Nicholls SJ,Puri R,Anderson T,et al.Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial[J].JAMA,2016,316(22):2373-2384.

更新日期/Last Update: 1900-01-01